Programming Innate Memory Responses to promote host defense against SARS-CoV-2 Pneumonia

  • Funded by Canadian Institutes of Health Research (CIHR)
  • Total publications:0 publications

Grant number: 504830

Grant search

Key facts

  • Disease

    COVID-19
  • start year

    2024
  • Known Financial Commitments (USD)

    $74,271.6
  • Funder

    Canadian Institutes of Health Research (CIHR)
  • Principal Investigator

    Divangahi Maziar
  • Research Location

    Canada
  • Lead Research Institution

    Research Institute of the McGill University Health Centre
  • Research Priority Alignment

    N/A
  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Disease pathogenesis

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Globally, respiratory infections cause more than 4 million deaths per year, with influenza virus (e.g. H1N1) and tuberculosis (TB) being major causes of mortality and morbidity. While viral pneumonias remain a global threat, the COVID-19 pandemic underlines the need for developing novel therapies that protect against emerging viruses. Host survival during infection in vital organs, such as the lung, requires a delicate balance between host resistance (eliminating the pathogens), and disease tolerance (minimizing collateral tissue damage). In fact, most pulmonary-virus related deaths (1-5%) result from a dysregulated host immune response to the virus (Immunopathology) rather than the cytopathic effects of the virus itself. Thus, it can be argued that pulmonary viruses are not the main threat; rather, it is the host's own immune-inflammatory response that jeopardizes host fitness/survival. However, the mechanism of how the immune system becomes dysregulated to the point of causing such massive immunopathology and how we can reverse this pathological process are currently not well understood. This proposal aims to address this fundamental question and design a therapeutic approach to prevent the severe COVID-19 disease.